Abstract
BackgroundThe Human papillomavirus (HPV) is a common sexually transmitted infection that generally goes unnoticed due to a lack of symptoms; however, HPV can lead to anogenital warts and, in chronic cases, cervical cancer. The Merck pharmaceutical company developed a commercial version of a quadrivalent recombinant non-infectious vaccine that was tested in preclinical research. This vaccine targets serotypes HPV16 and HPV18, which cause an estimated 70% of all cervical cancers, as well as serotypes HPV6 and HPV11, which cause 90% of external genital warts.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Internet Journal of Academic Physician Assistants
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
